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There is considerable indirect and some direct evidence that 
immune mechanisms can play an important role in control­
ling the growth of melanoma. In mice, melanoma can be 
prevented with vaccines. Consequently, even though natu­
rally occurring immunosurveillance may not be sufficiently 
T he concept that immune mechanisms are important in resistance to cancer is controversial. Some believe they play a major role in the occurrence or progression of cancer, others believe they are interesting but clini­cally irrelevant epiphenomena. This controversy re­
sults, in part, from failure to distinguish between two related but 
conceptually different hypotheses about the role of immunity in 
cancer. One is the concept of immunologic surveillance, the other 
of tumor protective immunity. Since these concepts are related, 
there is a mistaken tendency to conclude that observations that 
detract from one equally invalidate the other. Thus, criticisms of the 
immune-surveillance theory have raised doubts about the validity of 
tumor protective immunity. 
Differences Between Immunologic Surveillance and Tumor 
Protective Immunity Immunologic surveillance is a concept 
first formulated by Burnett in 1970 [1] to explain the puzzling 
observation that while potentially oncogenic mutations are com­
mon, cancer is actually rare. It has been calculated that 2 million 
potentially oncogenic mutations occur each day in each individual 
[2]. However, the lifetime risk that cancer will develop in any one 
individual is approximately 25%. Cancer occurs so rarely, Burnett 
postulated, because a major function of the immune system is to 
recognize and destroy abnormal mutated cells before they can 
evolve into tumors. 
Tumor protective immunity, on the other hand, refers to im­
mune mechanisms that increase resistance to cancer. These may be 
natural, preexisting mechanisms, responses that the patient de­
velops to his own tumor, or responses that are induced by various 
manipulations of the immune system. 
The critical difference between the two concepts is that immuno­
surveillance is proposed as the mechanism that prevents the devel­
opment of cancer in humans, while tumor protective immunity 
refers to mechanisms that increase resistance to cancer whether or 
not they prevent the disease. 
Critique ofImmunosurveillance The concept of immunosur­
veillance was criticized almost as soon as it was formulated [3]. The 
principal criticism was, and still is, that the incidence of cancer is 
usually not increased in animals or humans with immune deficiency 
apart from tumors of the lymphoreticular system and of the skin [4]. 
Why these two types of tumors occur more frequently in immuno-
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potent to prevent melanoma, it is possible that the prophy­
lactic augmentation of immunity to melanoma with vaccines 
may eventually rermit this cancer to be prevented in humans. 
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suppressed patients is not clear. However, since in most cases the 
patients are on immunosuppressive drugs, it may be a result of an 
oncogenic effect of the drugs used rather than of immunosuppres­
sion. In any event, the lack of an increase in more-common tumors 
(such as those of the breast, lung, and colon) implies that immunity 
is not the mechanism which prevents the development of most 
spontaneous tumors. By extension, this criticism has cast doubt on 
the practical relevance of any kind of immune mechanism to tumor 
growth. 
The Analogy to Infectious Diseases Even though immunosur­
veillance may or may not play a role in preventing cancer, immune 
mechanisms may nonetheless be important in augmenting resist­
ance to tumors. An appropriate analogy is with the role of immunity 
in infectious diseases. There, even though natural immunity by 
itself may not be capable of preventing an initial infection, immune 
mechanisms are nonetheless critical in increasing resistance to in­
fection once it occurs and in speeding resolution. If appropriately 
stimulated with vaccines, immunity to infectious diseases can be so 
potentiated that disease is prevented. This is also true in the case of 
cancer, where there is considerable evidence that immune mecha­
nisms increase resistance to this disease. Furthermore, as described 
subsequently, there is evidence that stimulation of tumor immunity 
with vaccines may be able to prevent cancer, even though "natural" 
immunosurveillance may be unable to do so. 
Evidence for Tumor Protective Immunity The evidence that 
immune mechanism can augment resistance to cancer is compel­
ling, though mostly indirect. It consists of the following observa­
tions. 
The Growth of Melanoma in Humans Is Influenced by Host Factors 
(5,6): The most dramatic demonstration of this phenomenon is 
the spontaneous and complete regression of widely disseminated 
melanoma. This is a rare, but well-documented event. Less-dra­
matic, partial regression of melanoma is much more common. It is 
seen histologically in 15% - 20% of primary melanomas. There can 
be a prolonged latent period, which can be longer than 20 years 
between removal of primary melanoma and the appearance of meta­
static lesions. During this time tumor cells are present in the body, 
but somehow do not grow. Metastatic disease may be present with­
out a detectable primary lesion and, conversely, melanoma cells may 
be present in the circulation without metastasis developing. Both 
these events suggest that melanoma cells, primary and metastatic, 
respectively, have been destroyed. All these observations indicate 
that host factors are capable of slowing the progression of melanoma 
and even causing its regression, although in most cases they are not 
sufficiently potent to prevent ultimate progression of the disease. 
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Host Factors Can Selectively Destroy P igment Cel/s, Both Normal and 
Mal ignant: The most dramatic demonstration of this is vitiligo. In 
vitiligo melanocytes are selectively destroyed, leading to patchy 
depigmentation of the skin, without damage to other cells in the 
skin. While the cause of vitiligo is not known, it is suspected to be an 
autoimmune disease [7]. Vitiligo is an experiment of nature which 
achieves the goal of melanoma immunotherapy, i.e., the selective 
destruction of pigment cells. 
The occurrence of depigmentation around primary melanoma 
and the "halo" nevi phenomenon are other demonstrations of the 
body's ability to selectively destroy pigment cells. Lastly, as men­
tioned above, there is histologic and clinical evidence of melanoma 
cell destruction in many primary melanomas. 
The host factors responsible for the selective destruction of pig­
ment cells are more than interesting, but irrelevant, epiphenomena. 
We [8] and others [9,10] have observed that the progression of 
melanoma is significantly slower in patients with pigment-cell de­
struction, as evidenced by areas of hypo pigmentation in normal skin 
around primary lesions of melanoma or in vitiligo-like patches away 
from the tumor, than in patients without this response. These host 
mechanisms, which inhibit or destroy normal melanocytes, may 
also be capable of slowing the growth of this cancer. 
Melanoma Can St imulate Immune Reponses In V ivo, and These Responses 
Can K ill Melanoma Cells In V itro [5]: Melanoma cells express anti­
gens which differ qualitatively and/or quantitatively from those on 
normal adult tisues. Humoral and/or cellular immune responses to 
melanoma are present in animals or humans with melanoma. These 
antibodies and immune cells can kill melanoma cells in vitro. The 
implications of these observations are that melanoma cells are suffi­
ciently different from normal adult cells to be recognized as foreign 
and to trigger immune responses in the tumor-bearing host, and 
that these responses have the capacity to destroy melanoma cells. 
Melanoma antigens in humans appear to be weak immunogens. 
As a result, antibody and cellular responses to melanoma in patients 
with this cancer are the exception rather than the rule [11-13]. 
Furthermore, immune responses to melanoma are complex both in 
their variety and in their effect. While some responses may damage 
melanoma cells and hinder tumor growth, others may protect these 
cells and enhance tumor growth [5]. This may explain why immune 
responses to melanoma are rare, and why the development of effec­
tive immunotherapy has been so difficult. 
Immunost imulation Can Delay, Wh ile Immunosuppress ion Can En­
hance, Melanoma Growth: Active immunotherapy with melanoma 
vaccines can significantly increase the resistance of mice to other­
wise lethal doses of melanoma cells [14]. Passive transfer of specific 
immune cells or specific monoclonal antibodies can also increase the 
resistance of animals to melanoma challenge and even cause regres­
sion of established disease. Conversely, immunosuppression of ani­
mals by thymectomy or by administration of antilymphocyte serum 
leads to more aggressive melanoma growth. The same may be true 
in humans. As described below, the growth of melanoma in humans 
may be slowed by immunization to melanoma vaccines. As de­
scribed elsewhere in this issue, the incidence of melanoma in immu­
nosuppressed patients is 4 to 8 times greater than expected. 
These observations are the most important indications that im­
mune mechanisms do have a protective role in vivo and, further­
more, that they can be manipulated to give desirable therapeutic 
results. Although these conclusions are based predominantly on the 
results of animal experiments, they hopefully apply to humans. 
Implications of Tumor Protective Immunity for Immuno­
therapy The involvement of immune mechanisms in the progres­
sion of melanoma has sparked an intense effort to develop effective 
methods of augmenting immunity to melanoma. A discussion of 
these is beyond the scope of this article, but the major approaches 
currently under investigation are summarized in Table I. At present 
all these approaches are experimental. None have been shown to 
clearly prolong the survival of patients with melanoma. Intrale­
sional injections of several agents (BCG, lymphokines) will regu-
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Table I. Immunotherapeutic Approaches to Melanoma 
Nonspecific 
Active 
BeG 
Vaccinia 
Levamisole 
Interferon 
Interleukin-2 (IL-2) 
Intralesional lymphokines 
Passive 
Phytohemagglutinin-stimulated 
lymphocytes 
IL-2 activated (LAK) cells 
Specific 
Active 
Tumor vaccine 
Passive 
Monoclonal antibodies 
Tumor infiltrating lymphocytes 
larly cause the regression of both injected and noninjected cutane­
ous nodules of melanoma, but do not seem to slow the overall 
progession of the disease. 
Immunosurveillance and Tumor Vaccines Even though the 
concept of immunosurveillance may not be valid, immunity may 
still be important in melanoma prevention. It is useful to return to 
the analogy with infectious diseases. Although not prevented by 
naturally occurring immunity, infectious diseases can be prevented 
by vaccine immunization. Similarly, although naturally occurring 
immune responses to melanoma may not be sufficiently potent to 
prevent the occurrence of this cancer, it may nonetheless prove 
possible to prevent it by stimulating melanoma immunity with vac­
cines. This may, in fact, be easier to achieve than immunotherapy of 
established disease. In mice it is easier to prevent melanoma by 
vaccine immunization than it is to treat established disease. 
In view of the relevance of tumor vaccines to melanoma preven­
tion, it is worthwhile to briefly summarize the status of this field. 
Melanoma vaccines are effective in animals, but their status in 
humans is still highly experimental. In mice, active immunization 
to melanoma vaccines prepared from whole tumor cells or from 
partially purified antigenic extracts will render mice resistant to 
challenge by otherwise lethal doses of melanoma cells [14-16]. The 
vaccines are weak. Multiple immunizations must be given to confer 
strong tumor-protective immunity. However, these experiments 
establish in principle that melanoma can be prevented by vaccines 
[17-21]. 
In humans, several melanoma vaccines are currently under inves­
tigation. They appear to be relatively safe. The major toxicities are 
avoidable. They include persistent skin ulceration at the site of 
immunization due to the use of overly toxic adjuvants, or infections 
due to contamination of the melanoma cells used for vaccine pro­
duction. Human melanoma vaccines are immunologically active. 
They can augment antibody and/or cellular immune responses to 
melanoma in some patients [21]. However, the immunogenicity of 
current vaccines is weak. They fail to boost immunity to melanoma 
in many patients. Attempts are being made to overcome this prob­
lem by using novel adjuvants and/or immunomodulators. The clin­
ical effectiveness of the present generation of melanoma vaccines is 
unclear. Their use has, in some cases, been associated with regres­
sion or delayed progression of established disease [18-21]. In our 
own studies, the disease-free interval in patients with Stage II mela­
noma (metastasis to regional nodes) was prolonged in patients with 
a cellular immune response to melanoma vaccine immunotherapy 
[22]. These results are promising, but difficult to evaluate because 
the progression of melanoma is erratic and no study has been ade­
quately controlled. 
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